Predictive Oncology Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POAI research report →
Companywww.predictive-oncology.com
Predictive Oncology Inc. , a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline.
- CEO
- Raymond F. Vennare
- IPO
- 2010
- Employees
- 23
- HQ
- Pittsburgh, MN, US
Price Chart
Valuation
- Market Cap
- $3.57M
- P/E
- -0.46
- P/S
- 346.20
- P/B
- 2.70
- EV/EBITDA
- -0.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -325.17%
- Op Margin
- -58805.87%
- Net Margin
- -474020.63%
- ROE
- -10705.18%
- ROIC
- -70.91%
Growth & Income
- Revenue
- $125.28K · -92.28%
- Net Income
- $-233,095,203 · -1810.42%
- EPS
- $-13.37 · -496.87%
- Op Income
- $-28,425,165
- FCF YoY
- 16.77%
Performance & Tape
- 52W High
- $45.90
- 52W Low
- $1.21
- 50D MA
- $8.42
- 200D MA
- $13.27
- Beta
- 1.35
- Avg Volume
- 141.65K
Get TickerSpark's AI analysis on POAI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Blacher Joshua | other | 9,389 |
Our POAI Coverage
We haven't published any research on POAI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate POAI Report →